Andere Sprachen Hua Medicine (Shanghai) Ltd.

Aktien

A2N463

KYG4644K1022

2552

Verzögert Hong Kong S.E. Andere Börsenplätze 05:46:02 03.05.2024			% 5 Tage	% 1. Jan.
1.58 ^HKD	-1.86%		-0.63%	-19.80%

28.03.	Hua Medicine (Shanghai) Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
2023	Hua Medicine (Shanghai) Ltd. ernennt Yi Zhang zum Executive Director mit Wirkung zum 1. Januar 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024	29.12.
Hua Medicine Intends to Conduct Trials of Diabetes Drug in US	21.12.
Hua Medicine Submits Investigational New Drug Application with the U.S. Food and Drug Administration for the 2Nd Generation Glucokinase Allosteric Activator	21.12.
China Includes Hua Medicine's Type 2 Diabetes Medication in Drug Reimbursement List	14.12.
Hua Medicine's Unit Receives 800 Million Yuan for Development of Diabetes Drug	22.11.
Hua Medicine Ltd. Announces Board and Committee Changes	12.10.23
Hua Medicine Announces 2023 Interim Results	25.08.23
Hua Medicine Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24.08.23
Hua Medicine Signs Distribution Agreement with Digital Healthcare Platform	11.04.23
Hua Medicine Ltd. Announces Resignation of Mr. Junling Liu as Independent Non-Executive Director and Change in Composition of the Board Committees	31.03.23
Hua Medicine Shrinks Loss in 2022 as Revenue Witnesses a Boost	29.03.23
Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	29.03.23
Hua Medicine Makes 49 Million Yuan of HuaTangNing Sales Since Launch	17.02.23
Hua Medicine Receives 400 Million Yuan in Milestone Payments for Diabetes Treatment	08.02.23
Hua Medicine Ltd. Announces Directorate and Committee Changes	30.12.22
Hua Medicine Announces Demise of Walter Teh-Ming Kwauk, an Independent Non-Executive Director	24.11.22
Hua Medicine Unit Buys 100% Stake in Diabetes Drug Research Company	18.11.22
China OKs Hua Medicine's New Drug Application for Type 2 Diabetes Treatment; Shares slipped 11%	10.10.22
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China	10.10.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Hua Medicine (Shanghai) Ltd.

Aktien

A2N463

KYG4644K1022

2552

Andere Sprachen

Filter